Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | MPO | P05164 | 8/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31708139 | 0.86 | HTR1A (0.66) | HTR1AMPOHTR2AHTR6HTR7 | |
| SCHEMBL25029800 | 0.80 | MPO (0.45) | HTR1AMPOHTR2AHTR6SLC6A4 | |
| SCHEMBL25030304 | 0.79 | MPO (0.48) | HTR1AMPOHTR2ASLC6A4MTNR1A | |
| SCHEMBL25381818 | 0.78 | HTR1A (0.67) | HTR1AMPOHTR2AHTR6HTR7 | |
| SCHEMBL25030287 | 0.77 | HTR2A (0.76) | HTR1AMPOHTR2AHTR6HTR7 | |
| SCHEMBL29992340 | 0.77 | HTR2A (0.76) | HTR1AMPOHTR2AHTR6HTR7 | |
| SCHEMBL25747597 | 0.77 | HTR1A (1.00) | HTR1AMPOHTR2AHTR6SLC6A4 | |
| SCHEMBL31708041 | 0.76 | MPO (0.57) | MPOHTR2ASLC6A4MTNR1AMTNR1B | |
| SCHEMBL25029861 | 0.76 | MPO (0.44) | HTR1AMPOHTR2AHTR6SLC6A4 | |
| SCHEMBL25029590 | 0.72 | MPO (0.56) | HTR1AMPOHTR2AHTR6SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635492-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |